PathWhiz

Pathway Description

Brivudine Action Pathway

Homo sapiens

Drug Action Pathway

Brivudine is a drug used to treat herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries. Brivudine exerts its antiviral activity by a selective inhibition at the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. Foscarnet inhibits the activity of DNA polymerase by competing with its substrate dGTP. Less viral proteins produced, fewer viruses can form.

References

Brivudine pathway References

Rabasseda X: Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 May;39(5):359-71. doi: 10.1358/dot.2003.39.5.740221.

Pubmed: 12861349

Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.

Pubmed: 29126136

Highlighted elements will appear in red.

Highlight Compounds

	Brivudine
	dGTP

Highlight Proteins

	ABC transporter, substrate-binding lipoprotein
	DNA polymerase catalytic subunit

Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.

Visualize Compound Data